S. Tomizawa

523 total citations
17 papers, 366 citations indexed

About

S. Tomizawa is a scholar working on Nephrology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, S. Tomizawa has authored 17 papers receiving a total of 366 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Nephrology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in S. Tomizawa's work include Renal Diseases and Glomerulopathies (8 papers), Platelet Disorders and Treatments (2 papers) and Genomic variations and chromosomal abnormalities (2 papers). S. Tomizawa is often cited by papers focused on Renal Diseases and Glomerulopathies (8 papers), Platelet Disorders and Treatments (2 papers) and Genomic variations and chromosomal abnormalities (2 papers). S. Tomizawa collaborates with scholars based in Japan and United States. S. Tomizawa's co-authors include Takayoshi Kuroume, Hiroshi Hayakawa, Takayuki Kasahara, Hidehiko Fujinaka, Makoto Uchiyama, Taketo Otsuka, Eishin Yaoita, Shigeyuki Suzuki, Kosçak Maruyama and Yutaka Yoshida and has published in prestigious journals such as Human Molecular Genetics, Vaccine and Pediatric Research.

In The Last Decade

S. Tomizawa

17 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Tomizawa Japan 12 189 133 62 47 47 17 366
Mietta Meroni Italy 13 94 0.5× 71 0.5× 34 0.5× 59 1.3× 46 1.0× 36 443
Ting-Chi Lu United States 8 239 1.3× 187 1.4× 108 1.7× 22 0.5× 22 0.5× 9 445
Changming Zhang China 9 158 0.8× 137 1.0× 51 0.8× 34 0.7× 32 0.7× 18 352
David H. Clyne United States 8 84 0.4× 145 1.1× 20 0.3× 26 0.6× 28 0.6× 10 304
Jillian N.M. Ilsley United States 9 47 0.2× 116 0.9× 31 0.5× 28 0.6× 63 1.3× 9 593
E McCafferty United States 10 168 0.9× 57 0.4× 112 1.8× 8 0.2× 23 0.5× 14 329
Patricia R. Wahl Switzerland 12 155 0.8× 285 2.1× 75 1.2× 155 3.3× 40 0.9× 16 628
William J. Hammack United States 12 30 0.2× 109 0.8× 52 0.8× 18 0.4× 27 0.6× 20 312
P. G. Scheurlen Germany 11 39 0.2× 130 1.0× 84 1.4× 45 1.0× 55 1.2× 54 383
Jiannan Li China 11 85 0.4× 91 0.7× 76 1.2× 31 0.7× 113 2.4× 28 350

Countries citing papers authored by S. Tomizawa

Since Specialization
Citations

This map shows the geographic impact of S. Tomizawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Tomizawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Tomizawa more than expected).

Fields of papers citing papers by S. Tomizawa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Tomizawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Tomizawa. The network helps show where S. Tomizawa may publish in the future.

Co-authorship network of co-authors of S. Tomizawa

This figure shows the co-authorship network connecting the top 25 collaborators of S. Tomizawa. A scholar is included among the top collaborators of S. Tomizawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Tomizawa. S. Tomizawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Tamura, Masaru, Masaki Hosoya, Tomoko Iida, et al.. (2013). Overdosage of Hand2 causes limb and heart defects in the human chromosomal disorder partial trisomy distal 4q. Human Molecular Genetics. 22(12). 2471–2481. 33 indexed citations
2.
Iida, Tomoko, Hidehiko Fujinaka, Bo Xu, et al.. (2013). Decreased urinary calbindin 1 levels in proteinuric rats and humans with distal nephron segment injuries. Clinical and Experimental Nephrology. 18(3). 432–443. 17 indexed citations
3.
Fujinaka, Hidehiko, Koichi Katsuyama, Keiko Yamamoto, et al.. (2010). Expression and localization of insulin‐like growth factor binding proteins in normal and proteinuric kidney glomeruli. Nephrology. 15(7). 700–709. 22 indexed citations
4.
Katsuyama, Koichi, Hidehiko Fujinaka, Keiko Yamamoto, et al.. (2009). Expression of the Chemokine Fractalkine (FKN/CX3CL1) by Podocytes in Normal and Proteinuric Rat Kidney Glomerulus. Nephron Experimental Nephrology. 113(2). e45–e56. 8 indexed citations
5.
Fujinaka, Hidehiko, Masaaki Nameta, Asako Matsuki, et al.. (2007). Periglomerular accumulation of dendritic cells in rat crescentic glomerulonephritis. Journal of Nephrology. 20(3). 357–363. 16 indexed citations
6.
Otsuka, Taketo, Hidehiko Fujinaka, Koichi Katsuyama, et al.. (2007). Influenza vaccination for severely multiply handicapped persons/children in the 2005–2006 season. Vaccine. 25(23). 4521–4524. 7 indexed citations
7.
Otsuka, Taketo, et al.. (2005). Duplication of chromosome 4q: Renal pathology of two siblings. American Journal of Medical Genetics Part A. 134A(3). 330–333. 26 indexed citations
8.
Kasahara, Takayuki, et al.. (2001). Prognosis of acute poststreptococcal glomerulonephritis (APSGN) is excellent in children, when adequately diagnosed. Pediatrics International. 43(4). 364–367. 33 indexed citations
9.
Hayakawa, Hiroshi, et al.. (1998). Influence of age at onset on the outcome of steroid-sensitive nephrotic syndrome. Pediatric Nephrology. 12(6). 467–470. 58 indexed citations
10.
Suzuki, Jun, et al.. (1994). Purification of Two Types of TNF Inhibitors in the Urine of the Patient with Chronic Glomerulonephritis. ˜The œNephron journals/Nephron journals. 66(4). 386–390. 4 indexed citations
11.
Maruyama, Kenta, et al.. (1992). Inhibition of Vascular Permeability Factor Production by Ciclosporin in Minimal Change Nephrotic Syndrome. ˜The œNephron journals/Nephron journals. 62(1). 27–30. 23 indexed citations
12.
Maruyama, Kenichi, et al.. (1989). Effect of Supernatants Derived from T Lymphocyte Culture in Minimal Change Nephrotic Syndrome on Rat Kidney Capillaries. ˜The œNephron journals/Nephron journals. 51(1). 73–76. 33 indexed citations
13.
Maruyama, K., et al.. (1988). Demonstration of the presence of digoxin-like immunoreactive substance (DLIS) in the serum and urine in children with nephrotic syndrome.. PubMed. 29(5). 244–7. 6 indexed citations
14.
Tomizawa, S., Kosçak Maruyama, Naoki Nagasawa, Shigeyuki Suzuki, & Takayoshi Kuroume. (1985). Studies of Vascular Permeability Factor derived from T Lymphocytes and Inhibitory Effect of Plasma on Its Production in Minimal Change Nephrotic Syndrome. ˜The œNephron journals/Nephron journals. 41(2). 157–160. 32 indexed citations
15.
Ito, Sadayoshi, et al.. (1980). IMMUNOGENETIC ASPECT IN THE PATIENTS WITH GN. Pediatric Research. 14(8). 1004–1004. 1 indexed citations
16.
Tomizawa, S., et al.. (1979). Studies of T Lymphocyte Function and Inhibitory Factors in Minimal Change Nephrotic Syndrome. ˜The œNephron journals/Nephron journals. 24(4). 179–182. 19 indexed citations
17.
Hata, T., Yosuke Sano, Kan Kanamori, et al.. (1954). Carzinophilin, a new tumor inhibitory substance produced by streptomyces. I.. PubMed. 7(4). 107–12. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026